	US 11,931,423 B2
	Glucose oxidase-nanoparticle bioconjugates for cancer treatment
Dexing Zeng, Pittsburgh, PA (US); Di Gao, Sewickley, PA (US); and Jiamin Wu, Pittsburgh, PA (US)
Assigned to UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, Pittsburgh, PA (US)
Filed by UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, Pittsburgh, PA (US)
Filed on Nov. 21, 2019, as Appl. No. 16/691,030.
Application 16/691,030 is a continuation of application No. PCT/US2018/034554, filed on May 25, 2018.
Claims priority of provisional application 62/511,717, filed on May 26, 2017.
Prior Publication US 2020/0085966 A1, Mar. 19, 2020
Int. Cl. A61K 47/68 (2017.01); A61B 5/0515 (2021.01); A61B 5/055 (2006.01); A61K 47/69 (2017.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01)

CPC A61K 47/6815 (2017.08) [A61B 5/0515 (2013.01); A61B 5/055 (2013.01); A61K 47/6811 (2017.08); A61K 47/6851 (2017.08); A61K 47/6923 (2017.08); A61P 35/00 (2018.01); C07K 16/2827 (2013.01); C07K 16/2842 (2013.01); C07K 16/2863 (2013.01); C07K 16/2866 (2013.01); C07K 16/32 (2013.01)]

7 Claims

1. A bioconjugate comprising:

(a) a superparamagnetic iron oxide nanoparticle functionalized with a first bioorthogonal ligation moiety selected from the group consisting of tetrazine, an azide, a tetrazole, and combinations thereof, wherein the nanoparticle has a diameter of about 4 nm to about 8 nm; and

(b) a glucose oxidase conjugated to the superparamagnetic iron oxide nanoparticle, wherein the glucose oxidase is functionalized with a second bioorthogonal ligation moiety selected from the group consisting of trans-cyclooctene, cyclooctyne, an alkyne, an alkene, photo-DIBO, cyclopropenone, and combinations thereof.

2. The bioconjugate of claim 1, further comprising a targeting probe, wherein the targeting probe is the antibody cetuximab, wherein the antibody cetuximab is conjugated to the glucose oxidase.